Acadia Pharmaceuticals Stock

The recent performance of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in the market spoke loud and clear to investors as ACAD saw more than 2. Stock analysis for ACADIA Pharmaceuticals Inc (ACAD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. ACADIA Pharmaceuticals Inc. 's stock rating is based on fundamental analysis. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare ACADIA Pharmaceuticals against related stocks people have also bought like CELG, GILD, TEVA, and MU. 5 times 2024 revenue, which isn't exactly cheap for a mid-cap biopharma stock. It operates through development and commercialization of innovative medicines segment. Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) stock continued its rally on September 21 st, 2018 after surging 26. is a biopharmaceutical company. Read more Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint. EVR ratings range from zero through ten with ten being the highest or most volatile. In addition to competitive compensation, we offer a great mix of programs to benefit you and your family. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. Get ACADIA Pharmaceuticals Inc (DR6-FF:Frankfurt Stock Exchange) real-time stock quotes, news and financial information from CNBC. However, the stock crashed by 15. Analyst Ratings For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), the stock jumped 44. 5 hours ago · Notable Technical and Performance analysis of the ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Spoke is the definitive source of curated information on millions of companies, people and industries. See insights on ACADIA Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. 86% during the previous week performance. A decreasing shares outstanding over time may be the result of company buybacks. No Buyout just to buy back at bear market prices when everyone else is selling on the news. Get breaking news and analysis on ACADIA Pharmaceuticals Inc. Technical chart claims that ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to. Get the latest ACADIA Pharmaceuticals Inc. -traded ETFs. EVR is a weighted average which accurately assesses how sensitive an individual stock is to its earnings announcement. ACAD Real Time Stock Quote - Get ACADIA Pharmaceuticals Inc. It focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Free real-time stock charts for ACADIA Pharmaceuticals Inc (ACAD). However, the stock crashed by 15. 1% as of 12:00 p. ACADIA Pharmaceuticals Inc. 02/share level. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. (ACAD), a biopharmaceutical company focused on the development and commercialization. Our investment research resources are provided to help you make informed investment decisions. Where are ACADIA Pharmaceuticals' (NASDAQ:ACAD) earnings headed? View ACAD's earnings history, next earnings date and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. This is the main ACADIA Pharmaceuticals Inc stock chart and current price. ACAD - ACADIA Pharmaceuticals Inc. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Published on October 14, Bonus Biotech Stock Pick:. Barron's also provides information on historical stock ratings, target prices, company earnings, market. 83, Acadia Pharmaceuticals Inc has a higher such ratio than 95. X When you're researching the best stocks to buy and watch, be sure to pay. Get the latest broker recommendations from Zacks Investment Research. The company said pimavanserin achieved "robust statistical superiority" over placebo, with longer time to. Stephen Davis , CEO of ACADIA Pharmaceuticals Inc. proactiveinvestors. 4% since reporting last quarter. Find the latest ACADIA Pharmaceuticals Inc. Our experienced leadership team shares a common focus: to improve patients' lives. 1% during the next 3 months and, with 90% probability hold a price between $50. At Walletinvestor. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. Displays all buying and selling activity for company insiders. Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release. 15 Wall Street analysts have issued ratings and price targets for ACADIA Pharmaceuticals in the last 12 months. 08% gain for the last 2 weeks. ACADIA Pharmaceuticals Inc. Acadia (ACAD) delivered earnings and revenue surprises of 29. Brian Feroldi has no position in any stocks mentioned. What provoked this double-digit sell-off? Acadia's shares fell victim to the politically charged drug-pricing debate in the United States. 's (ACAD) stock price could be set to double as analysts forecast soaring revenue in the near future. ACAD / ACADIA Pharmaceuticals, Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet. Wall Street analysts expect ACADIA Pharmaceuticals will release losses per share of $0. ACADIA Pharmaceuticals Inc. View the latest ACAD stock quote and chart on MSN Money. Common Stock Common Stock (ACAD) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Displays all buying and selling activity for company insiders. 26 for its downside target. Acadia (ACAD) delivered earnings and revenue surprises of 29. This compares to loss of $0. 30, 2019-- ACADIA Pharmaceuticals Inc. 5 hours ago · Notable Technical and Performance analysis of the ACADIA Pharmaceuticals Inc. Find the latest ACADIA Pharmaceuticals Inc. The spark? Acadia's shares perked up today in. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended September. 00 per share. ACADIA Pharmaceuticals Inc. Many analysts have provided their estimated foresights on ACADIA Pharmaceuticals Inc. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. ACAD dividend history, yield, payout ratio, and stock fundamentals. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,. (ACAD) stock, price quote and chart, trading and investing tools. 3, selling for $36. Get the latest price and volume on Acadia Pharmaceuticals in IBD stock charts. Share your opinion and gain insight from other stock traders and investors. $250,000,000 of its common stock. 07 and year to date. Analyze performance using advanced charting and trend analysis. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. (NASDAQ:ACAD) to $56. Rash, urticaria, and reactions consistent with angioedema (e. Nuplazid is a drug that was given approval by the U. Acadia Pharmaceuticals Description Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. Each job description includes a link for applying and submitting your resume to us online. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares. The company is holding 150. Its stock price has been found in the range of 14. SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals Inc. 0033) compared to placebo in time to relapse of dementia-related psychosis (DRP), explains biotech specialist John McCamant, editor of The Medical Technology Stock Letter. The company said pimavanserin achieved "robust statistical superiority" over placebo, with longer time to. Acadia Pharmaceuticals upgraded to buy at Canaccord Genuity MarketWatch. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Previously, Dr. ACADIA Pharmaceuticals (NASDAQ:ACAD) stock fell more than 6% on Monday as one of the company's drugs is being investigated for its efficacy. Nuplazid is an atypical antipsychotic drug (2nd generation antipsychotic) and label warnings, plus mortality issues have. ACADIA Pharmaceuticals Inc. There are 11 Buy Ratings, 3 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock. 3 Mid-Cap Biotech Stocks To Consider Buying Now. Acadia Pharmaceuticals is now considered extended and out of buy range after clearing a 28. 51 below the opening price on the mentioned day. See today’s analyst top recommended stocks >>. 32 mark, then the market for ACADIA Pharmaceuticals Inc. All content on FT. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a price to the public of. 15 Wall Street analysts have issued ratings and price targets for ACADIA Pharmaceuticals in the last 12 months. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to ad. No Buyout just to buy back at bear market prices when everyone else is selling on the news. View Adam Morgan’s profile on LinkedIn, the world's largest professional community. Acadia Pharmaceuticals (ACAD) stock price, charts, trades & the US's most popular discussion forums. Start a 14-day free trial to Morningstar Premium to unlock our take on ACAD. 08, as the stock lost 6. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. 44 per share a year ago. 5% of US equities we're observing. Executive Summary. X When you're researching the best stocks to buy and watch, be sure to pay. Yesterday, Acadia Pharmaceuticals closed at $25. 00 per share, Baker Bros. On Friday, shares of ACADIA Pharmaceuticals Inc. 1% during the next 3 months and, with 90% probability hold a price between $50. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a price to. Common Stock Common Stock (ACAD) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. The company is holding 150. Five analysts have provided estimates for ACADIA Pharmaceuticals' earnings, with the lowest sales estimate coming in at $85. Find the latest quotes for (ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Me. Still, it did not stop the Baker Brothers Advisors L. Barron's also provides information on historical stock ratings, target prices, company earnings, market. A Look At ACADIA Pharmaceuticals (NASDAQ:ACAD) With the previous 100-day trading volume average of 1. 10 on July 17, 2015. rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. in a report released on Monday, AnalystRatings. Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock? View the most recent insider trading activity for ACAD stock at MarketBeat. Displays all buying and selling activity for company insiders. ACAD stock rating and analysis - ACADIA Pharmaceuticals : a summary of key financial strength and profitability metrics. Will ACADIA Pharmaceuticals Inc NASDAQ:ACAD meet your expectations? ACADIA Pharmaceuticals Inc headquartered in San Diego, California, United States is reporting their earnings on 07/31/2019 after the bell. The Food and Drug Administration is re-evaluating the safety of a medication that was approved despite concerns that not enough was known about the drug's risks. Acadia Pharmaceuticals stock rockets after late-stage trial of pimavanserin mets primary endpoint. ACADIA Pharmaceuticals Inc. ACAD Real Time Stock Quote - Get ACADIA Pharmaceuticals Inc. Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley FoolAfter years of dismay, Acadia Pharmaceuticals' (NASDAQ:ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid. Looking for insights on Acadia-pharmaceuticals (NASDAQ:ACAD) stock? View ACAD's stock ratings, price targets, earnings, commentary and news at Smarter Analyst. (NASDAQ: ACAD) 5. [ACAD] saw a change by -2. 2/share to $43. (NASDAQ:ACAD) reportedly Sold 29,792 shares of the company's stock at an average price of 40 for a total transaction amount of $1,191,680. Buy, sell and hold ratings for ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. 5 times 2024 revenue, which isn't exactly cheap for a mid-cap biopharma stock. View today's stock price, news and analysis for ACADIA Pharmaceuticals Inc. With having a -1. It operates through development and commercialization of innovative medicines segment. —Acadia Pharmaceuticals faced a setback in July with the failure of a late-stage trial that was testing pimavanserin—which the company’s sells under the name Nuplazid as a treatment for. 5 million in common stock. Technical chart claims that ACADIA Pharmaceuticals Inc. 08% gain for the last 2 weeks. 97% of gains with the last five trading sessions. Executive Summary. Acadia (ACAD) delivered earnings and revenue surprises of 29. Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock: 1. ETF market. The firm. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. , investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. (ACAD) stock discussion in Yahoo Finance's forum. stock market and it is a holding in 55 U. Get prepared with the key expectations. 5 times 2024 revenue, which isn't exactly cheap for a mid-cap biopharma stock. ACADIA Pharmaceuticals To Announce Third Quarter 2019 Financial Results On October 30, 2019. ACADIA Pharmaceuticals Inc. exchanged hands with 3042926 shares contrast to its average daily volume of 2. Advanced Chart, Quote and financial news from the leading provider and award-winning BigCharts. A stock with a beta more. Free forex prices, toplists, indices and lots more. Barron's also provides information on historical stock ratings, target prices, company earnings, market. (ACAD) rocketed 87% toward a 4-year high in premarket trading Monday, after the biopharmaceutical company said a phase 3 trial of its treatment for dementia-related psychosis met its primary endpoint. , the stock's short ratio clocks in at 11. Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley FoolAfter years of dismay, Acadia Pharmaceuticals' (NASDAQ:ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid. Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. ACAD has around 14. 78 per share versus a previous $37. This page contains information on users’ sentiments for the ACADIA Pharmaceuticals Inc stock, which are displayed both on charts of different periods of time and on a detailed table. 82M shares with keeping 150. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization. Equities research analysts expect ACADIA Pharmaceuticals Inc. Free real-time stock charts for ACADIA Pharmaceuticals Inc (ACAD). The Food and Drug Administration is re-evaluating the safety of a medication that was approved despite concerns that not enough was known about the drug's risks. and all the companies you research at NASDAQ. Get the latest ACADIA Pharmaceuticals Inc. Providing exceptional laboratory services for over twenty years. 26 for its downside target. 3 Mid-Cap Biotech Stocks To Consider Buying Now. They currently have $50. Acadia Pharmaceuticals stock price target raised to $50 from $21 at SVB Leerink MarketWatch. Analysts weighed in today on biopharmaceutical giants Valeant Pharmaceuticals Intl Inc and ACADIA Pharmaceuticals Inc. 77 buy point in a second-stage consolidation. Get the latest ACADIA Pharmaceuticals Inc. Performance Indicators of ACADIA Pharmaceuticals Inc. Research ACADIA Pharmaceuticals Inc. The company filed a $200 million secondary offering on November 26 to raise additional capital as they continue to grow. A friend of mine is a corporate officer at La Jolla Pharmaceuticals. com Acadia Pharmaceuticals (ACAD) reported positive data on September 23 showing improved depression symptom in patients with Parkinson's Disease. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation. View ACADIA Pharmaceuticals Inc. 11% and monthly performance stands at 13. 07:27 AM ET. About Acadia Pharmaceuticals Inc Boxer Muhammad Ali, "Back to the Future" actor Michael J. ACADIA Pharmaceuticals Inc. 84 a share, at $38. X When looking for the best stocks to buy and watch, be sure to pay attention. is a company in the U. (ACAD) is working its way for to the bottom in the market today. , Miramar, FL 33025 U. Positive Developments for These 3 Biotech Stocks We review Acadia Pharmaceuticals, The Medicines Company, and Flexion Therapeutics. ACADIA Pharmaceuticals Inc. , a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. At current price of $41. The company has collaboration agreements with Allergan, Inc. Acadia Pharmaceuticals stock sells off on safety concerns for Nuplazid. Yesterday, the shares gained 4. Street forecast for the quarter ending June 2019 is $-0. Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. (NASDAQ:ACAD) last week. ACADIA Pharmaceuticals, Inc. Then there is the risk that Trump could carpet bomb the pharma/biotech industry tonight. The higher this short ratio, the more investors are expecting that the stock is going to fall. 73, making it a high for the given period, the value of the stock dropped by -5. 00 target price on the biopharmaceutical company's stock, up from their prior. RSS feed en Thu, 12 Sep 2019 22:14:34 -0400 http://blogs. com provides this link as a service and assumes no responsibility for any information presented on external websites. After years of dismay, Acadia Pharmaceuticals' (NASDAQ:ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid. ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Chart, Quote and financial news from the leading provider and award-winning BigCharts. 17 September 2019 ACADIA Pharmaceuticals Prices Public Offering of Common Stock. Real time Acadia Pharmaceuticals (ACAD) stock price quote, stock graph, news & analysis. 18%, while ACAD stocks collected +2. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock, offered at a price to the. 11% and monthly performance stands at 13. 30, 2019-- ACADIA Pharmaceuticals Inc. After years of dismay, Acadia Pharmaceuticals' (NASDAQ: ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid. 79, a current ratio of 6. 21% of ACAD’s float, the number of shares shorted have fallen by -405600. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock. Overview: Detailed price quote, earnings report, user sentiment and news. Find the latest ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the closing of its previously announced underwritten public offering of 7,187,500 shares of its common stock, which includes. is a biopharmaceutical company. So under a best case scenario, this biopharma stock is probably trading at somewhere along the lines of 6. 00 per share. Monday, September 09, 2019. stock price. , (ACAD)’s stock has risen by 20. ACADIA Pharmaceuticals Inc. In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017. has shown a weekly performance of 3. Get ACAD stock quote information for ACADIA-Pharmaceuticals-Inc, including a stock overview, one-click scorecard, industry position, and the latest headlines. (ACAD) is working its way for to the bottom in the market today. Acadia Pharmaceuticals Inc. SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. The all-time high ACADIA Pharmaceuticals stock closing price was 50. Their average twelve-month price target is $49. have plunged 40% in 2018. This number entails how much is being traded in the open market. Total Rewards. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous. We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of our products and product candidates. Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates. (NASDAQ:ACAD) is one of the worst performers on the stock market today. (NASDAQ:ACAD) reportedly Sold 2,983 shares of the company’s stock at an average price of 39. Phase III HARMONY trial conducted by Acadia Pharmaceuticals (ACAD) recently delivered robust statistically superior data (p=0. 24 or more within the next month. ACADIA Pharmaceuticals has a 12 month low of $14. ACAD has around 14. [ACAD] saw a change by -1. 27 to a high of $43. 79%, respectively, for the quarter ended September 2019. Providing exceptional laboratory services for over twenty years. It operates through development and commercialization of innovative medicines segment. The stock has shown a quarterly performance of 47. 2m and a trailing-twelve month of -US$276. 42 points lower from last closing price of $41. has been trampled with about everything else in this market, most hard hit have been the small biotechs. Prices of a stock will move throughout the day. Avadel Pharmaceuticals. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, October 30th. View ACADIA Pharmaceuticals Inc. Markets as the company shares are 5. View Acadia Pharmaceuticals Inc. (ACAD) is working its way for to the bottom in the market today. Acadia Pharmaceuticals plans to offer $250 million of its stock in a public offering, the San Diego biomedical company said Tuesday. Not only was the study successful, but it was stopped early because of how well patients did in the study. 97% of gains with the last five trading sessions. is a company in the U. 02/share level. , the stock's short ratio clocks in at 11. ACADIA PHARMACEUTICALS INC form 4 sec filings insider trading. (NASDAQ: ACAD) Posted July 24, 2017 by Christian Tharp, CMT: ACAD. Bloomberg the Company & Its Products Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Terminal Demo Request. Its stock price has been found in the range of 14. 64% lower) from its previous close of $43. The shorts are running away from ACADIA Pharmaceuticals Inc. ST Invest is a wholly owned subsidiary of StockTwits, Inc. And for technical investors. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Nonetheless, with regard to ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public. Insider trades (SEC Form 4) for ACADIA Pharmaceuticals Inc. com we predict future values with technical analysis for wide selection of stocks like ACADIA Pharmaceuticals Inc. There are a large number of possible reasons why the investing community may be interested in the stock. ACADIA Pharmaceuticals Inc. Today, Royal Bank of Canada initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is having an overwhelmingly strong start to the trading session this morning, and for good reason. 10 on July 17, 2015. In depth view into ACAD (ACADIA Pharmaceuticals) stock including the latest price, news, dividend history, earnings information and financials. 79%, respectively, for the quarter ended September 2019. Where are ACADIA Pharmaceuticals' (NASDAQ:ACAD) earnings headed? View ACAD's earnings history, next earnings date and consensus earnings estimates from top-rated Wall Street analysts at MarketBeat. 85 and move down -4. Whereas 4 of them predict the stock is a hold. The fact-checkers, whose work is more and more important for those who prefer facts over lies, police the line between fact and falsehood on a day-to-day basis, and do a great job. Today, my small contribution is to pass along a very good overview that reflects on one of Trump’s favorite overarching falsehoods. Namely: Trump describes an America in which everything was going down the tubes under  Obama, which is why we needed Trump to make America great again. And he claims that this project has come to fruition, with America setting records for prosperity under his leadership and guidance. “Obama bad; Trump good” is pretty much his analysis in all areas and measurement of U.S. activity, especially economically. Even if this were true, it would reflect poorly on Trump’s character, but it has the added problem of being false, a big lie made up of many small ones. Personally, I don’t assume that all economic measurements directly reflect the leadership of whoever occupies the Oval Office, nor am I smart enough to figure out what causes what in the economy. But the idea that presidents get the credit or the blame for the economy during their tenure is a political fact of life. Trump, in his adorable, immodest mendacity, not only claims credit for everything good that happens in the economy, but tells people, literally and specifically, that they have to vote for him even if they hate him, because without his guidance, their 401(k) accounts “will go down the tubes.” That would be offensive even if it were true, but it is utterly false. The stock market has been on a 10-year run of steady gains that began in 2009, the year Barack Obama was inaugurated. But why would anyone care about that? It’s only an unarguable, stubborn fact. Still, speaking of facts, there are so many measurements and indicators of how the economy is doing, that those not committed to an honest investigation can find evidence for whatever they want to believe. Trump and his most committed followers want to believe that everything was terrible under Barack Obama and great under Trump. That’s baloney. Anyone who believes that believes something false. And a series of charts and graphs published Monday in the Washington Post and explained by Economics Correspondent Heather Long provides the data that tells the tale. The details are complicated. Click through to the link above and you’ll learn much. But the overview is pretty simply this: The U.S. economy had a major meltdown in the last year of the George W. Bush presidency. Again, I’m not smart enough to know how much of this was Bush’s “fault.” But he had been in office for six years when the trouble started. So, if it’s ever reasonable to hold a president accountable for the performance of the economy, the timeline is bad for Bush. GDP growth went negative. Job growth fell sharply and then went negative. Median household income shrank. The Dow Jones Industrial Average dropped by more than 5,000 points! U.S. manufacturing output plunged, as did average home values, as did average hourly wages, as did measures of consumer confidence and most other indicators of economic health. (Backup for that is contained in the Post piece I linked to above.) Barack Obama inherited that mess of falling numbers, which continued during his first year in office, 2009, as he put in place policies designed to turn it around. By 2010, Obama’s second year, pretty much all of the negative numbers had turned positive. By the time Obama was up for reelection in 2012, all of them were headed in the right direction, which is certainly among the reasons voters gave him a second term by a solid (not landslide) margin. Basically, all of those good numbers continued throughout the second Obama term. The U.S. GDP, probably the single best measure of how the economy is doing, grew by 2.9 percent in 2015, which was Obama’s seventh year in office and was the best GDP growth number since before the crash of the late Bush years. GDP growth slowed to 1.6 percent in 2016, which may have been among the indicators that supported Trump’s campaign-year argument that everything was going to hell and only he could fix it. During the first year of Trump, GDP growth grew to 2.4 percent, which is decent but not great and anyway, a reasonable person would acknowledge that — to the degree that economic performance is to the credit or blame of the president — the performance in the first year of a new president is a mixture of the old and new policies. In Trump’s second year, 2018, the GDP grew 2.9 percent, equaling Obama’s best year, and so far in 2019, the growth rate has fallen to 2.1 percent, a mediocre number and a decline for which Trump presumably accepts no responsibility and blames either Nancy Pelosi, Ilhan Omar or, if he can swing it, Barack Obama. I suppose it’s natural for a president to want to take credit for everything good that happens on his (or someday her) watch, but not the blame for anything bad. Trump is more blatant about this than most. If we judge by his bad but remarkably steady approval ratings (today, according to the average maintained by 538.com, it’s 41.9 approval/ 53.7 disapproval) the pretty-good economy is not winning him new supporters, nor is his constant exaggeration of his accomplishments costing him many old ones). I already offered it above, but the full Washington Post workup of these numbers, and commentary/explanation by economics correspondent Heather Long, are here. On a related matter, if you care about what used to be called fiscal conservatism, which is the belief that federal debt and deficit matter, here’s a New York Times analysis, based on Congressional Budget Office data, suggesting that the annual budget deficit (that’s the amount the government borrows every year reflecting that amount by which federal spending exceeds revenues) which fell steadily during the Obama years, from a peak of $1.4 trillion at the beginning of the Obama administration, to $585 billion in 2016 (Obama’s last year in office), will be back up to $960 billion this fiscal year, and back over $1 trillion in 2020. (Here’s the New York Times piece detailing those numbers.) Trump is currently floating various tax cuts for the rich and the poor that will presumably worsen those projections, if passed. As the Times piece reported: